Press Releases
November 2, 2020
SBP Schedules Conference Call on Nov 12, 2020 to Report Q3 2020 Financial Results
September 1, 2020
SBP Closes $10.5 Million Public Offering of Common Stock and Warrants
August 30, 2020
SBP Announces Pricing of $10.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
August 11, 2020
SBP Provides Business Update and Reports Q2 2020 Financial Results
July 16, 2020
SBP Appoints Jennifer K. Simpson, Ph.D., as President and CEO
- Company founder Michael T. Cullen, M.D. will continue to serve as Executive Chairman
May 13, 2020
SBP Provides Business Update and Reports Q1 2020 Financial Results
April 6, 2020
SBP Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer
March 24, 2020
SBP Provides Business Update and Reports Operating Results for FY2019
- Enrollment completed in fourth cohort of Phase 1a/1b trial of SBP-101 in pancreatic cancer; expansion cohort initiated
- Interim Phase 1 data presented at ASCO GI meeting demonstrated tolerability and tumor response in treatment-naïve patients with metastatic pancreatic cancer
January 28, 2020